Promising Developments in Cullinan Management’s CLN-978 TCE for Autoimmune Diseases Drive Buy Rating
Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune ...
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial ...
BioSpace15d
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming ...
Mena FN16d
Cullinan Therapeutics To Present Preclinical Data For CLN-978, A CD19-Directed T Cell Engager, At ACR Convergence 2024
“These preclinical data show that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting the broad development of CLN-978 as a potential new therapeutic option ...